Return On Equity
74%
Trailing 12 months · Through 30 Sep 2026
YoY relative change: -6.9%
Period Q3 2026 · Filed 12 Nov 2026
Return On Equity
74%
Trailing 12 months · Through 30 Sep 2026
YoY relative change: -6.9%
Return On Assets
-62%
Third-party reference; reporting period not verified
Operating Margin
-5721%
Third-party reference; reporting period not verified
Current Ratio
0.97x
Third-party reference; reporting period not verified
Quick Ratio
0.91x
Third-party reference; reporting period not verified
NetIncomeLoss YoY
11%
Trailing 12 months · Through 30 Sep 2026
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
74%
Trailing 12 months · 30 Sep 2026
|
-6.9% |
| Return On Assets |
-62%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
-5721%
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.97x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
0.91x
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
11%
Trailing 12 months · 30 Sep 2026
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
5,133,645
Period-end balance · 06 Nov 2026
|
+9.4% |
| Common Stock, Shares, Outstanding |
5,103,083
Period-end balance · 30 Sep 2026
|
|
| Common Stock, Value, Issued |
$52
Period-end balance · 30 Sep 2026
|
+13% |
| Weighted Average Number of Shares Outstanding, Basic |
5,102,659
Reported period · 30 Sep 2026
|
+15% |
| Weighted Average Number of Shares Outstanding, Diluted |
5,102,659
Reported period · 30 Sep 2026
|
+15% |
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$4,489,059
Period-end balance · 30 Sep 2026
|
+22% |
| Accrued Liabilities, Current |
$1,316,611
Period-end balance · 30 Sep 2026
|
+4.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
-$704,156
Period-end balance · 30 Sep 2026
|
-1.7% |
| Assets |
$8,243,058
Period-end balance · 30 Sep 2026
|
-45% |
| Assets, Current |
$7,903,898
Period-end balance · 30 Sep 2026
|
-46% |
| Cash and Cash Equivalents, at Carrying Value |
$7,470,862
Period-end balance · 30 Sep 2026
|
-21% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$7,470,862
Period-end balance · 30 Sep 2026
|
-48% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares Authorized |
150,000,000
Period-end balance · 30 Sep 2026
|
0% |
| Common Stock, Shares, Issued |
5,103,083
Period-end balance · 30 Sep 2026
|
+11% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
-$11,036,997
Trailing 12 months · 30 Sep 2026
|
+11% |
| Earnings Per Share, Basic |
-2.21
Trailing 12 months · 30 Sep 2026
|
+26% |
| Earnings Per Share, Diluted |
-2.21
Trailing 12 months · 30 Sep 2026
|
+26% |
| General and Administrative Expense |
$5,803,998
Trailing 12 months · 30 Sep 2026
|
+0.5% |
| Interest Expense |
-$36,000
Trailing 12 months · 30 Sep 2026
|
+67% |
| Liabilities and Equity |
$8,243,058
Period-end balance · 30 Sep 2026
|
-45% |
| Liabilities, Current |
$8,175,239
Period-end balance · 30 Sep 2026
|
-39% |
| Operating Income (Loss) |
-$11,441,403
Trailing 12 months · 30 Sep 2026
|
+8% |
| Other Assets, Current |
$85,152
Period-end balance · 30 Sep 2026
|
|
| Property, Plant and Equipment, Net |
$339,160
Period-end balance · 30 Sep 2026
|
-21% |
| Research and Development Expense |
$6,408,506
Trailing 12 months · 30 Sep 2026
|
+13% |
| Retained Earnings (Accumulated Deficit) |
-$165,098,847
Period-end balance · 30 Sep 2026
|
-7.2% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$200,000
Reported period · 30 Sep 2026
|
|
| Share-based Payment Arrangement, Expense |
$1,948,000
Trailing 12 months · 30 Sep 2026
|
-21% |
| Stockholders' Equity Attributable to Parent |
-$16,251,418
Period-end balance · 30 Sep 2026
|
-20% |
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q3 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
12 Nov 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 12 Nov 2026.
Benchmark Context
Return On Equity is down about 6.9% versus the comparable prior period.
Compared with
Compared with MiNK Therapeutics, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-11-06) highlights Return On Equity 74.1%, Return On Assets -61.6%, and Operating Margin -5720.7%.
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
Use these links to compare INKT - MiNK Therapeutics, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: 11%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
69.2/100
Balanced Confidence medium
74%
Metric score 100.0/100
-62%
Metric score 0.0/100
Return On Equity, Current Ratio, and Quick Ratio
Return On Assets and Operating Margin
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
CIK / security context first